-
Morning Market Losers
Thursday, November 20, 2014 - 10:49am | 205Datawatch (NASDAQ: DWCH) shares fell 16.74% to $9.15 after the company reported a Q4 loss of $0.18 per share. Lexicon Pharmaceuticals (NASDAQ: LXRX) dipped 15.20% to $1.06 after the company announced a proposed convertible senior notes offering. Jumei International Holding (NYSE: JMEI) shares fell...
-
Lexicon Announces Proposed Common Stock Offering Of $50M In Shares
Wednesday, November 19, 2014 - 5:02pm | 345Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it commenced an offering to sell, subject to market and other conditions, $50,000,000 of shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to...
-
Events for the Week of Nov. 17-21, 2014
Monday, November 17, 2014 - 2:13pm | 1059Morgan Stanley Global Consumer Conference – Nov. 18 to Nov. 19 - New York City Companies to participate :< /u> Dean Foods Co. (NYSE: DF) ServiceMaster Global Holdings, Inc. (NYSE: SERV) Michael Kors Holdings Limited (NYSE: KORS) The Cheesecake Factory Incorporated (NASDAQ: CAKE) Iconix...
-
Morning Market Losers
Thursday, November 13, 2014 - 10:49am | 250Revance Therapeutics (NASDAQ: RVNC) shares dipped 28.33% to $15.05 after the company reported a Q3 net loss of $14.0 million, versus a year-ago loss of $8.9 million. Local (NASDAQ: LOCM) shares fell 24.63% to $1.30 after the company reported a Q3 loss of $0.06 per share on revenue of $18.10 million...
-
UPDATE: Ligand Pharmaceuticals Q3 Earnings Beat Street View
Monday, October 27, 2014 - 9:00am | 228Ligand Pharmaceuticals (NASDAQ: LGND) reported upbeat earnings for the third quarter. The La Jolla, California-based company posted quarterly net income of $1.3 million, or $0.06 per share, versus $2.0 million, or $0.09 per share, in the year-ago period. Excluding certain items, the company earned...
-
Mid-Morning Market Update: Markets Mostly Flat; Costco Posts Upbeat Earnings
Wednesday, October 8, 2014 - 10:00am | 646Following the market opening Wednesday, the Dow traded up 0.03 percent to 16,724.66 while the NASDAQ declined 0.01 percent to 4,385.00. The S&P also fell, dropping 0.03 percent to 1,934.51. Leading and Lagging Sectors In trading on Wednesday, utilities shares were relative leaders, up on...
-
Morning Market Movers
Wednesday, October 8, 2014 - 9:36am | 174GT Advanced Technologies (NASDAQ: GTAT) jumped 40.50% to $1.70 after surging 51.25% on Tuesday. Trio-Tech International (NYSE: TRT) climbed 9.45% to $3.59 on Q4 results. Blackhawk Network Holdings (NASDAQ: HAWK) shares surged 9.25% to $34.50 after the company reported upbeat Q3 results. Chimerix (...
-
Neurocrine Initiates Tourette Syndrome Clinical Trial
Thursday, October 2, 2014 - 4:03pm | 386Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome. The T-Force study is an open-label, multi-...
-
Benzinga's Top Downgrades
Tuesday, August 19, 2014 - 9:00am | 132Analysts at Piper Jaffray downgraded Guess? (NYSE: GES) from Overweight to Neutral. The target price for Guess has been lowered from $32 to $25. Guess' shares closed at $26.24 yesterday. Baird downgraded Ingersoll-Rand plc (Ireland) (NYSE: IR) from Outperform to Neutral. The target price for...
-
Gabelli Downgrades Lexicon Pharmaceuticals To Hold
Tuesday, August 19, 2014 - 8:43am | 46Analysts at Gabelli downgraded Lexicon Pharmaceuticals (NASDAQ: LXRX) from Buy to Hold. Lexicon Pharma shares have dropped 27.43% over the past 52 weeks, while the S&P 500 index has gained 19.79% in the same period. Lexicon Pharma's shares closed at $1.64 yesterday.
-
UPDATE: Avion Pharma Reports Signing of Commercial License Deal with Ligand Pharma for Development, Commercialization of Four Captisol-Enabled Programs, Ligand Entitled to Upfront Payment
Friday, August 15, 2014 - 9:33am | 176Avion Pharmaceuticals, LLC, announces the signing of a commercial license agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) for the development and commercialization of four Captisol-enabled programs. Under the terms of the agreement, Ligand is entitled to receive an up-front...
-
Morning Market Movers
Wednesday, August 13, 2014 - 9:44am | 206LiveDeal (NASDAQ: LIVE) shares climbed 21.82% to $4.69 after the company reported a 340% surge in its FQ3 revenue. Versar (NYSE: VSR) gained 14.25% to $3.58 after the company announced a $98.3 million contract at Dover Air Force Base. Canadian Solar (NASDAQ: CSIQ) shares jumped 12.58% to $28.11...
-
Benzinga's Top Initiations
Monday, August 4, 2014 - 9:40am | 80Analysts at Jefferies initiated coverage on La Jolla Pharma (NASDAQ: LJPC) with a Buy rating. The target price for La Jolla Pharma is set to $25. La Jolla Pharma's shares closed at $9.40 on Friday. Imperial Capital initiated coverage on shares of Diamond Resorts (NYSE: DRII) with a Outperform...
-
Jefferies Initiates La Jolla Pharma With Buy
Monday, August 4, 2014 - 8:39am | 64Analysts at Jefferies initiated coverage on La Jolla Pharma (NASDAQ: LJPC) with a Buy rating. The target price for La Jolla Pharma is set to $25. La Jolla Pharma shares have surged 168.57% over the past 52 weeks, while the S&P 500 index has gained 12.60% in the same period. La Jolla Pharma's...
-
UPDATE: Metabolix Reports Placement Deal with Investors to Raise $25M in Financing
Monday, August 4, 2014 - 8:35am | 523Metabolix, Inc. (NASDAQ: MBLX), an advanced biomaterials company focused on sustainable solutions for the plastics and chemicals industries, today announced that it has entered into an agreement with Jack W. Schuler, Oracle Investment Management, Inc., Birchview Capital, certain members of the...